OncLive TV

Justin F. Gainor, MD, assistant professor of medicine, Harvard Medical School, attending physician, Massachusetts General Hospital, discusses the future of treatment for patients with EGFR-positive non-small cell lung cancer.

Peter R. Dottino, MD, professor of obstetrics, gynecology and reproductive science, Mount Sinai Hospital, discusses targeted therapies for patients with ovarian cancer.

Owen O'Connor, MD, PhD, professor of medicine and Experimental Therapeutics, director of the Center for Lymphoid Malignancies, Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, discusses the role of obinutuzumab (Gazyva) in the treatment of patients with follicular lymphoma.

Joseph A. Califano, MD, professor of surgery, University of California, San Diego, discusses the role of multidisciplinary care for patients with head and neck cancer.

Jeffrey M. Holzbeierlein, MD, professor, director of Urologic Oncology, Department of Urology, University of Kansas Medical Center, discusses the management guidelines for patients with bladder cancer.

Bijal D. Shah, MD, medical oncology, Moffit Cancer Center, discusses the importance of chimeric antigen receptor (CAR) T-cell therapy for patients with acute lymphoblastic leukemia (ALL).

Shubham Pant, MD, associate professor, The University of Texas MD Anderson Cancer Center, discusses the current treatment landscape of colorectal cancer.

Kanti R. Rai, MD, discusses older populations with chronic lymphocytic leukemia.

Shaji K. Kumar, MD, professor of medicine, Mayo Clinic, discusses genetic abnormalities in multiple myeloma.

Eric Jonasch, MD, professor, The University of Texas MD Anderson Cancer Center, discusses the CABOSUN study in renal cell carcinoma (RCC).

William R. Berry, MD, medical oncologist, Duke University, discusses novel imaging techniques for patients with prostate cancer.

Josh H. Heinzerling, MD, Department of Radiation Oncology, Levine Cancer Institute, discusses the development of new treatment regimens for patients with early-stage lung cancer.

Peter Soyer, MD, academic dermatologist, professor, The University of Queensland Diamantina Institute, discusses the role of technology in melanoma.

Leo I. Gordon, MD, professor of medicine, Feinberg School of Medicine, Northwestern University, discusses the role of checkpoint inhibitors for patients with hematologic malignancies.

Raghava R. Induru, MD, medical oncologist, Levine Cancer Institute, discusses other mutations in lung cancer.

Mario M. Leitao Jr, MD, FACOG, FACS, fellowship director, gynecology service, director, Minimal Access and Robotic Surgery Program, Department of Surgery, Memorial Sloan Kettering Cancer Center, discusses the importance of surgery for patients with ovarian cancer.

Michelle E. Melisko, MD, clinical professor of medicine, University of California, San Francisco (UCSF), explains the discussion around duration of use of aromatase inhibitors in patients who have estrogen receptor-positive breast cancer.

Brant Inman, MD, surgical oncologist, urologic oncologist, Duke Cancer Center, discusses novel immunotherapy combinations for patients with bladder cancer.

Jared Weiss, MD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses how and when to biopsy patients for lung cancer.

Jane N. Winter, MD, professor of medicine, Division of Hematology/Oncology, Northwestern University, discusses copanlisib (Aliqopa) in follicular lymphoma.

A. David McCollum, MD, Baylor-Sammons Cancer Center, discusses drug sequences for patients with colorectal cancer (CRC).

Bijal D. Shah, MD, medical oncology, Moffitt Cancer Center, discusses the sequencing of agents for patients with mantle cell lymphoma (MCL).

Josh H. Heinzerling, MD, Department of Radiation Oncology, Levine Cancer Institute, discusses remaining challenges for treating stage III non–small cell lung cancer (NSCLC).

David S. Hong, MD, deputy chair, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses IPI-549 during The Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting.

Kelly Paulson, MD, fellow, Seattle Cancer Care Alliance, discusses acquired resistance to immunotherapy during The Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting.

Carlos Becerra, MD, physician, Texas Oncology, discusses emerging treatments for patients with pancreatic cancer.

Primo N. Lara Jr, MD, associate director for translational research, UC Davis Comprehensive Cancer Center, discusses the FDA approval of adjuvant sunitinib (Sutent) for high-risk patients with renal cell carcinoma (RCC).

Patrick Borgen, MD, chair, Department of Surgery, director, Breast Center, Maimonides Medical Center, discusses advancements in the treatment landscape of HER2-positive breast cancer.

A. David McCollum, MD, physician, Texas Oncology, discusses treatment options in the first-line setting for patients with colorectal cancer (CRC).

Jonathan N. Warner, MD, reconstructive urologist, City of Hope, discusses the future of surgery for patients with prostate cancer.